Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVEN: Brolucizumab vs Aflibercept in CRVO-related Macular Edema
NCT03810313Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of brolucizumab in macular edema secondary to central retinal vein occlusion (ME-CRVO) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Best-corrected Visual Acuity at 24 weeks. Started Jul 2019; status: terminated.
02
Drugs
brolucizumab
03
Conditions
macular edema secondary to central retinal vein occlusion (ME-CRVO)
Beyond the preview
Go deeper on NCT03810313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810313.